News
EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001
Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy CTX001 has been granted a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA).